[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334309-105":59,"doc-detail-334309-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","contemporary-trends-in-utilization-of-metastasectomy-in-the-era-of-targeted-and-immunotherapies","Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies","","Metastasectomy is an adjunct in metastatic cancer care, but the widespread adoption of targeted and immunotherapies has likely shifted its clinical role. Using the National Inpatient Sample, researchers examined U.S. utilization from 2016–2021 across five primary cancers eligible for these therapies. Procedure and secondary malignancy coding identified metastasectomy cases and enabled incidence-adjusted national estimates. Utilization rose for breast cancer and melanoma, while lung, colorectal, and renal cancers showed no significant change.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/contemporary-trends-in-utilization-of-metastasectomy-in-the-era-of-targeted-and-immunotherapies/334309/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/contemporary-trends-in-utilization-of-metastasectomy-in-the-era-of-targeted-and-immunotherapies/334309.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the study on metastasectomy trends?","Question",{"text":112,"@type":113},"To characterize utilization trends in metastasectomy across five primary cancers eligible for targeted and immunotherapies and to assess how these therapies may have altered its role.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients identified as undergoing metastasectomy?",{"text":117,"@type":113},"The National Inpatient Sample was used to include U.S. patients (2016–2021) with procedure codes for resections (lung, liver, adrenal gland, brain, small bowel) plus concurrent diagnosis codes for secondary malignant neoplasm at the site.",{"name":119,"@type":110,"acceptedAnswer":120},"Which cancers showed significant increases in metastasectomy utilization between 2016 and 2021?",{"text":121,"@type":113},"Breast cancer and melanoma showed significant increases in utilization over the study period.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334309,1790466452,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","DOI: 10. 1002/cncr.35664  \nORIGINAL ARTICLE  \nContemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies  \nJesse E. Passman MD, MSHP, MPH 1,2  | Michael J. Kallan MS3 |  \nJeffrey L. Roberson MD, MBA1 | Sara P. Ginzberg MD, MSHP1,2  | Wajid Amjad BS1 | Jacqueline M. Soegaard Ballester MD, MBMI1 | Gabriella Tortorello MD1  | Douglas Fraker MD1,4 | Giorgos C. Karakousis MD 1,4  | Edmund K. Bartlett MD5  | Heather Wachtel MD, MTR 1,4  \n1Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA  \n2Leonard Davis Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA 3Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA  \n4Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA 5Memorial Sloan Kettering Cancer Center, New York, New York, USA  \nCorrespondence  \nJesse E. Passman, Hospital of the University of Pennsylvania, 3400 Spruce St, Maloney Bldg, 4th Fl, Philadelphia, PA 19104, USA.  \nEmail: jesse. passman@pennmedicine. [upenn.edu](upenn.edu)  \nFunding information  \nNational Cancer Institute, Grant/Award Numbers: K08 CA270385, P30 CA008748  \nAbstract  \nBackground: Metastasectomy is a useful adjunct in the management of metastatic cancer. Widespread adoption of novel targeted and immunotherapies has improved the survival profiles of multiple malignancies, which has potentially altered the role of metastasectomy. This study aimed to characterize trends in metastasectomy across five primary cancers eligible for these therapies.  \nMethods: The National Inpatient Sample was used to identify patients who underwent metastasectomy in the United States (2016–2021). Patients with procedure codes for resection of the lung, liver, adrenal gland, brain, or small bowel and concurrent diagnosis codes for secondary malignant neoplasm of that site were included. Subjects were subcategorized by primary malignancy: colorectal cancer, lung cancer, breast cancer, melanoma, or renal cancer. Sample weights were used to produce national estimates, which were incidence adjusted by primary malignancy. Trends in utilization were calculated with average annual percent change (AAPC) and linear regression coefficients.  \nResults: Colorectal cancer was the most frequent indication for metastasectomy (n = 57,644 cases), followed by lung cancer (n = 55,090 cases), breast cancer (n = 12,616 cases), renal cancer (n = 8427 cases), and melanoma (n = 5658 cases). Utilization of metastasectomy increased over the study period for breast cancer (AAPC, þ10.6%; p = .013) and melanoma (AAPC, þ8.3%; p = .040) but did not change for lung cancer (AAPC, −1.6%; p = . 26), colorectal cancer (AAPC, þ0.3%; p = .83), or renal cancer (AAPC, þ2.3%; p = . 36).  \nConclusions: Between 2016 and 2021, utilization of metastasectomy increased significantly for melanoma and breast cancer. The role of metastasectomy will likely continue to develop as new treatment protocols improve survival profiles for patients with metastatic disease.  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2025;e35664.  \n[https://doi.org/10.1002/cncr.35664](https://doi.org/10.1002/cncr.35664)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 10  \nKEYWORDS  \nbreast cancer, colorectal cancer, lung cancer, melanoma, metastasectomy, renal cancer, targeted therapies  \nINTRODUCTION  \nTraditionally, metastatic cancer has been considered incurable. Systemic therapies have focused on disease control and symptom palliation. Surgery has hi","cbCaicOOZZnDhQAb","https://ap.wps.com/l/cbCaicOOZZnDhQAb","pdf",543346,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the purpose of the study on metastasectomy trends?\",\"answer\":\"To characterize utilization trends in metastasectomy across five primary cancers eligible for targeted and immunotherapies and to assess how these therapies may have altered its role.\"},{\"question\":\"How were patients identified as undergoing metastasectomy?\",\"answer\":\"The National Inpatient Sample was used to include U.S. patients (2016–2021) with procedure codes for resections (lung, liver, adrenal gland, brain, small bowel) plus concurrent diagnosis codes for secondary malignant neoplasm at the site.\"},{\"question\":\"Which cancers showed significant increases in metastasectomy utilization between 2016 and 2021?\",\"answer\":\"Breast cancer and melanoma showed significant increases in utilization over the study period.\"}]","Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies | PDF",1790006225,25]